Developing new treatments against cancer and autoimmune diseases thanks to its unique knowledge of the microbiota, Enterome signs a collaboration agreement with Nestlé Health Science targeting food allergies and chronic intestinal diseases.
Enterome announced on Monday the signing of a collaboration and license agreement with Nestlé Health Science, a subsidiary of the Swiss giant Nestlé. The two companies intend to work on the development of an experimental treatment, EB1010, developed from Enterome’s proprietary Mimicry platform and aimed at improving the management of patients suffering from food allergies or chronic inflammatory diseases of the intestine (IBD). Human trials of this drug candidate are due to begin in 2023.
Enterome, based in Paris and Genopole d’Evry, and Nestlé Health Science, headquartered in Lausanne, Switzerland, will also develop a portfolio of potential new treatments for food allergies from the Mimicry platform, focusing first on the most common, peanut allergy.
An initial contribution of 40 million euros from Nestlé Health Science
As part of this agreement, Enterome will benefit from an initial contribution of 40 million euros from Nestlé Health Science, partly in cash and partly by subscription to the capital of Enterome. The French firm is eligible for additional payments based on clinical and commercial milestones as well as, where applicable, royalties on net sales of the various products resulting from the partnership.
Scientific and Medical Director of Nestlé Health Science, Hans-Juergen Woerle, pointed out that globally around 220 million people suffer from food allergies, while IBD affects 7 million patients. “Through this collaboration, we aim to develop new treatments representing an important therapeutic need, unmet to date,” he said.
“We will generate new AllerMimics candidates using our highly productive Mimicry drug discovery platform, which has already enabled us to discover several small protein and peptide-based drug candidates forming a new therapeutic class across a broad spectrum. of therapeutic areas. AllerMimics are an intrinsically new class of specific antigens produced by the microbiome, which are similar to food allergens and which help the patient’s immune system to tolerate these specific allergens”, explained for his part Christophe Bonny, director Enterome scientist.
“Prevent or reduce the intensity of allergic reactions in the intestine”
“This collaboration will also allow us to advance the clinical development of the first candidate in our EndoMimics portfolio, EB1010. We believe that EB1010, administered orally, has the potential to prevent or reduce the intensity of allergic reactions in the gut. While also being evaluated in Chronic Inflammatory Bowel Disease, EB1010 may be indicated in many different forms of food allergy, potentially in combination with AllerMimics.”
Pierre Belichard, CEO of Enterome, said he was delighted with the conclusion of this agreement with Nestlé Health Science, the world leader in food allergies. For the manager, the conclusion of this collaboration agreement also highlights both the potential and the growing interest of manufacturers for the Mimicry platform as a source of new immunotherapies. “This milestone is all the more exciting following the recent clinical and immunological validation of the mode of action of EO2401, our first ready-to-use OncoMimics immunotherapy for glioblastoma and adrenal carcinoma,” he said. .